Fig. 5From: Incremental cost-utility of sevelamer relative to calcium carbonate for treatment of hyperphosphatemia among pre-dialysis chronic kidney disease patientsRelationship between incremental cost-effectiveness ration and hazard ratio for sevelamerBack to article page